Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
heredERA Breast Cancer
PACTR202212829625733Phase 3Recruiting
- Sponsor
- Roche
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of giredestrant, trastuzumab, pertuzumab and hyaluronidase in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Progression-Free Survival. Started Feb 2023; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on PACTR202212829625733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202212829625733.